Urologic Design Raises $1.2M for Male Incontinence Device

Removing a continence product before urination puts an unusually intimate design decision at the center of Urologic Design. The Branford, Connecticut medical-device company is developing a temporary urethral occlusion device for men with stress urinary incontinence, a condition whose management can shape ordinary decisions about clothes, activities and leaving home.

The company announced a $1.2M pre-seed close on October 29, 2026, led by Angel Investor Forum. HBS Alumni Angels of Boston, Haven Founders Fund, Connecticut Innovations, Yale Angels and individual investors participated. Urologic Design says the financing will support development, regulatory work and preparation for its first-in-human study.

The investment places patient usability alongside clinical development in the company's immediate work. Urologic Design's website says its planned study will assess preliminary safety and usability; the device remains investigational, has no FDA clearance or approval and is unavailable for sale. For an early medical-device company, the way someone handles the product is already part of the business proposition.

A clinical frustration becomes a design assignment

Co-founder and CSO David Hesse started Urologic Design after seeing patients struggle with continence management, according to the company. His clinical background gives that observation a specific setting: Yale School of Medicine identifies him as an associate professor of urology, with work spanning urologic oncology and other urologic conditions. That affiliation establishes professional experience without making Yale the sponsor of the company's product or planned trial.

The company describes a sterile, single-use device with a soft interior that expands after insertion and a string used for removal before urination. Its appeal rests on a proposed change in how a man manages leakage during the day. A small object can introduce its own practical demands, however, and those demands belong in the evaluation of the product alongside its intended function.

That is where the clinical observation becomes an operating assignment. The team has to learn whether the proposed sequence of use is acceptable to the people expected to perform it, and whether the device can be used safely. Comfort and convenience remain development objectives; presenting them as established outcomes would skip the very work this financing is intended to support.

There is useful discipline in the company's stated focus on preliminary safety and usability. It gives early human testing a defined purpose while leaving room for users to reveal difficulties that a design drawing or laboratory test cannot anticipate.

What the capital pays for, and what the records establish

The financing announcement describes a completed, oversubscribed pre-seed round. The stated work includes continued R&D, product refinement and testing, regulatory preparation and readiness for an initial clinical study. Urologic Design reports that it already has a prototype, intellectual-property protection and bench-testing experience, creating a technical starting point for the next phase.

An earlier SEC Form D amendment signed July 24, 2026 supplies a separate financial snapshot. It lists $610K sold against a $1.3M offering of convertible promissory notes, with a first sale dated July 9. The filing identifies Henry Ritter as CEO and manager, and David Hesse as CSO and manager, of Urologic Design, LLC, formed in 2022 and based in Branford.

The relationship between that offering and the October announcement is not explained in the reviewed sources, so the amounts should not be added to create a lifetime funding total. The October release describes its close as equity funding; the July document describes the instrument offered at that earlier point. Neither record supplies a disclosed valuation or a complete financing history.

For operators following the company, the practical significance is the work the new capital is assigned to support. Regulatory preparation, device development and initial human-use research need to advance together, with the results informing how the team describes the product to future clinicians and users.

The competition includes the routine a patient already knows

Male stress urinary incontinence sits within a broader category of bladder-control problems, and treatment depends on the individual condition. The National Institute of Diabetes and Digestive and Kidney Diseases describes a range of approaches, including pelvic-floor exercises, protective products and procedures such as male slings and artificial urinary sphincters. A funding announcement should not compress those different choices into a single claim that one new device can replace them all.

Urologic Design is proposing another way to manage leakage, with temporary use built into the concept. That places attention on how its intended users experience the product between clinical visits. Familiar products can be cumbersome and still be familiar; asking someone to adopt a different routine creates a learning and acceptance question as well as an engineering one.

For the company, that makes usability commercially consequential before a price or distribution channel has been disclosed. A future product's dimensions may be easy to explain, while the reasons a person would repeatedly choose it are more personal. The planned initial study offers a place to begin examining those questions, within its stated preliminary scope.

The funding therefore supports a close encounter between the design and the people it is intended to help. As Urologic Design prepares for that work, the men participating in its research will bring their own expectations about privacy, handling and daily use into the development process.